Biomark Diagnostics Inc. (FRA:20B)

Biomark Diagnostics Statistics

Total Valuation

FRA:20B has a market cap or net worth of EUR 23.33 million. The enterprise value is 22.87 million.

Market Cap	23.33M
Enterprise Value	22.87M

Important Dates

The last earnings date was Thursday, November 27, 2025.

Earnings Date	Nov 27, 2025
Ex-Dividend Date	n/a

Share Statistics

FRA:20B has 105.09 million shares outstanding. The number of shares has increased by 10.10% in one year.

Current Share Class	105.09M
Shares Outstanding	105.09M
Shares Change (YoY)	+10.10%
Shares Change (QoQ)	n/a
Owned by Insiders (%)	6.59%
Owned by Institutions (%)	n/a
Float	53.57M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	308.93
PB Ratio	44.16
P/TBV Ratio	44.16
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-22.60
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-26.30

Financial Position

The company has a current ratio of 1.73, with a Debt / Equity ratio of 0.93.

Current Ratio	1.73
Quick Ratio	1.73
Debt / Equity	0.93
Debt / EBITDA	n/a
Debt / FCF	-0.56
Interest Coverage	-42.29

Financial Efficiency

Return on Equity (ROE)	n/a
Return on Assets (ROA)	-79.14%
Return on Invested Capital (ROIC)	-103.04%
Return on Capital Employed (ROCE)	-197.52%
Revenue Per Employee	n/a
Profits Per Employee	n/a
Employee Count	n/a
Asset Turnover	0.09
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +57.48% in the last 52 weeks. The beta is -0.21, so FRA:20B's price volatility has been lower than the market average.

Beta (5Y)	-0.21
52-Week Price Change	+57.48%
50-Day Moving Average	0.19
200-Day Moving Average	0.17
Relative Strength Index (RSI)	62.00
Average Volume (20 Days)	10

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, FRA:20B had revenue of EUR 75,519 and -1.01 million in losses. Loss per share was -0.01.

Revenue	75,519
Gross Profit	75,519
Operating Income	-1.07M
Pretax Income	-1.01M
Net Income	-1.01M
EBITDA	-1.06M
EBIT	-1.07M
Loss Per Share	-0.01

Balance Sheet

The company has 945,756 in cash and 489,006 in debt, giving a net cash position of 456,750 or 0.00 per share.

Cash & Cash Equivalents	945,756
Total Debt	489,006
Net Cash	456,750
Net Cash Per Share	0.00
Equity (Book Value)	528,348
Book Value Per Share	0.01
Working Capital	445,283

Cash Flow

In the last 12 months, operating cash flow was -862,374 and capital expenditures -7,189, giving a free cash flow of -869,563.

Operating Cash Flow	-862,374
Capital Expenditures	-7,189
Free Cash Flow	-869,563
FCF Per Share	-0.01

Margins

Gross Margin	100.00%
Operating Margin	-1,413.46%
Pretax Margin	-1,340.24%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

FRA:20B does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-10.10%
Shareholder Yield	-10.10%
Earnings Yield	-4.34%
FCF Yield	-3.73%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

FRA:20B has an Altman Z-Score of -1.06 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-1.06
Piotroski F-Score	2